Drug intelligence / Profile preview

efavirenz nanoparticles

Development stage: Phase 1
Modality: Nanoparticles → Drug Delivery Systems
Administration: Oral

Overview

Efavirenz nanoparticles are a nanoformulation of the conventional HIV drug efavirenz, designed to enhance its solubility, bioavailability, and therapeutic efficacy. This formulation addresses the poor water solubility (10 μg/ml) and limited bioavailability (40-45%) of conventional efavirenz, which currently requires high doses (600-800 mg/day). By reducing particle size to the nanometer range (typically 99-200 nm), these formulations achieve significantly improved drug release profiles (95-100% within 1 hour compared to 23-58% of pure drug) and better cellular uptake.

Other names: NANO-efavirenzefavirenz nanosuspensionefavirenz nanocrystals

Targets

Human immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on efavirenz nanoparticles.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on efavirenz nanoparticles.

Explore the full profile